Amplify YieldShares Oil Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cambridge, mass.--(business wire)---- $amlx--amylyx pharmaceuticals announces interim data from ongoing phase 2 helios clinical trial.

New york, ny / accesswire / april 9, 2024 / if you suffered a loss on your amylyx pharmaceuticals, inc. (nasdaq:amlx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74968&wire=1 or contact joseph e. levi, esq.

New york, ny / accesswire / april 9, 2024 / if you suffered a loss on your amylyx pharmaceuticals, inc. (nasdaq:amlx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74944&wire=1 or contact joseph e. levi, esq.

New york, ny / accesswire / april 9, 2024 / if you suffered a loss on your amylyx pharmaceuticals, inc. (nasdaq:amlx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74879&wire=1 or contact joseph e. levi, esq.

Los angeles, ca / accesswire / april 9, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against amylyx pharmaceuticals, inc. ("amylyx" or "the company") (nasdaq:amlx) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between november 11, 2022 and november 8, 2023, inclusive (the "class period"), are encouraged to contact the firm before april 9, 2024.

Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%.

The decision to remove Relyvrio from the market comes after the drug failed a Phase 3 trial.

Amylyx Pharmaceuticals said on Thursday it would withdraw its amyotrophic lateral sclerosis (ALS) drug from the U.S. and Canada markets after the treatment failed in a crucial late-stage trial.

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

Amylyx's ALS drug failed a late-stage trial, raising questions about the future of the drug and the company itself.

Relyvrio, which is sold under the name Albrioza in Canada, is Amylyx's only product.

Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.

Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.

Investors may want to jump into oversold Russell 2000 stocks. For one, after a rough outing in 2023, smaller-cap stocks are starting to come back strong.

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.65 per share a year ago.